A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas.

Trial Profile

A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Topotecan (Primary) ; Veliparib (Primary)
  • Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 01 Feb 2017 Last checked against ClinicalTrials.gov record (NCT00553189).
    • 01 Feb 2017 Last checked against ClinicalTrials.gov record (NCT00553189).
    • 18 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top